Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders
Schizophrenia Bulletin · 2023
DOI: 10.1093/schbul/sbad100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Schizophrenia Bulletin, 2023. Verfasst von Xiaoyan Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory o…. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Bipolar Disorder, Attention Deficit Disorder with Hyperactivity. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background and hypothesis Psychiatric disorders impose a huge health and economic burden on modern society. However, there is currently no proven completely effective treatment available, partly owing to the inefficiency of drug target identification and validation. We aim to identify therapeutic targets relevant to psychiatric disorders by conducting Mendelian randomization (MR) analysis. Study design We performed genome-wide MR analysis by integrating expression quantitative trait loci (eQTL) of 4479 actionable genes that encode druggable proteins and genetic summary statistics from genome-wide association studies of psychiatric disorders. After conducting colocalization analysis on the brain MR findings, we employed protein quantitative trait loci (pQTL) data as genetic proposed instruments for intersecting the colocalized genes to provide further genetic evidence. Study results By performing MR and colocalization analysis with eQTL genetic instruments, we obtained 31 promising drug targets for psychiatric disorders, including 21 significant genes for schizophrenia, 7 for bipolar disorder, 2 for depression, 1 for attention deficit and hyperactivity (ADHD) and none for autism spectrum disorder. Combining MR results using pQTL genetic instruments, we finally proposed 8 drug-targeting genes supported by the strongest MR evidence, including gene ACE, BTN3A3, HAPLN4, MAPK3 and NEK4 for schizophrenia, gene NEK4 and HAPLN4 for bipolar disorder, and gene TIE1 for ADHD. Conclusions Our findings with genetic support were more likely to be to succeed in clinical trials. In addition, our study prioritizes approved drug targets for the development of new therapies and provides critical drug reuse opportunities for psychiatric disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Techn…
ORCID-Profile: Junfeng Xia
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, X., Shen, A., Zhao, Y., & Xia, J. (2023). Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbad100
Vancouver
Li X, Shen A, Zhao Y, Xia J. Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders. Schizophrenia Bulletin. 2023. doi:10.1093/schbul/sbad100
BibTeX
@article{Li2023,
author = {Li, Xiaoyan and Shen, Aotian and Zhao, Yiran and Xia, Junfeng},
title = {Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders},
journal = {Schizophrenia Bulletin},
year = {2023},
doi = {10.1093/schbul/sbad100}
}
EUVIMED